Skip to main content

Advertisement

SpringerLink
Log in

Review of Current Pneumococcal Vaccine Guidelines

  • COPD (J. Fanikos, Section Editor)
  • Published:
Current Emergency and Hospital Medicine Reports Aims and scope Submit manuscript

Abstract

Pneumococcal vaccination has been associated with a decline in the infectious disease burden caused by Streptococcus pneumoniae since it was incorporated into routine vaccination schedules for adults and children. In 2014, the Centers for Disease Control and Prevention updated its recommendations to include a single dose of a 13-valent pneumococcal conjugate vaccine for adults ≥65 years. The pediatric recommendations remain unchanged. This paper reviews the current vaccine recommendations for adults and children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Active Bacterial Core Surveillance (ABCs): Emerging infections program network. Unpublished data (2013). Atlanta: US Department of Health and Human Services, CDC; 2013.

  2. Centers for Disease Control and Prevention. Recommendations of the immunization practices advisory committee (ACIP) update: pneumococcal polysaccharide vaccine usage—United States. MMWR. 1984;33(20):273-6–281. http://www.cdc.gov/mmwr/preview/mmwrhtml/00031107.htm. Accessed 25 Feb 2015.

  3. •• Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep. 2010;59(RR-11). These are the official CDC recommendations for the use of pneumococcal vaccines in children.

  4. Pilishivili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41.

    Article  Google Scholar 

  5. •• Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822. These are the updated CDC recommendations for the use of pneumococcal vaccines in adults.

  6. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA; analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.

    Article  CAS  PubMed  Google Scholar 

  7. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2012;61(40):816–9.

    Google Scholar 

  8. • Bonten M, Huijts S, Bolkenbaas M, et al. Community acquired pneumonia immunization trial in adults (CAPiTA). Abstract no. 0595. IDSA Meeting 2014. https://idsa.confex.com/idsa/2014/webprogram/Paper47346.html. Accessed 17 Feb 2015. This abstract detailing the CAPiTA trial was one of primary factors leading to the change in pneumococcal vaccine recommendations in adults.

  9. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. Vaccine. 2013;31:3577–84.

    Article  CAS  PubMed  Google Scholar 

  10. Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31:3585–93.

    Article  CAS  PubMed  Google Scholar 

  11. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine. 2014;32:2364–74.

    Article  CAS  PubMed  Google Scholar 

  12. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187–95.

    Article  CAS  PubMed  Google Scholar 

  13. Preventing Pneumococcal Disease Among Infants and Young Children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2000;49(RR-9).

  14. Whitney CG. Cochlear implants and meningitis in children. Pediatr Infect Dis J. 2004;23:767–8.

    Article  PubMed  Google Scholar 

  15. Food and Drug Administration. Product approval information—licensing action, package insert: Prevnar 13 (pneumococcal 13-valent conjugate vaccine), Pfizer. Rockville: US Department of Health and Human Services, Food and Drug Administration; 2010. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm. Accessed 7 Feb 2015.

  16. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States. MMWR. 2013;62(25):521–4.

    Google Scholar 

  17. Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis. 2004;39(7):930.

    Article  PubMed  Google Scholar 

  18. Destefano F, Pfeifer D, Nohynek H. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ. 2008;86:373–80.

    Article  PubMed Central  PubMed  Google Scholar 

  19. PNEUMOVAX 23 (pneumococcal vaccine polyvalent) sterile, liquid vaccine for intramuscular or subcutaneous injection—prescribing information. http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf. Accessed 7 Feb 2015.

  20. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services; Food and Drug Administration; 2011. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf. Accessed 25 Feb 2015.

  21. Wise RP, Iskander J, Pratt RD, Campbell S, Ball R, Pless RP, et al. Post licensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA. 2004;292:1702–10.

    Article  CAS  PubMed  Google Scholar 

  22. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)—United States, 1991–2001. MMWR. 2003;52(1):1–24.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Communications, Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA

    Komal Bawa

  2. Pharmacy Department, University of California San Francisco, Box 0622, 521 Parnassus Avenue, Room C-152, San Francisco, CA, 94122, USA

    Megan Pintens

Authors
  1. Komal Bawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megan Pintens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Komal Bawa.

Additional information

This article is part of the Topical Collection on COPD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bawa, K., Pintens, M. Review of Current Pneumococcal Vaccine Guidelines. Curr Emerg Hosp Med Rep 3, 121–125 (2015). https://doi.org/10.1007/s40138-015-0078-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40138-015-0078-6

Keywords

Search

Navigation